# Section 9: The EoE Patient Journey — Why This Program Exists

Every disease has a clinical narrative and a lived one. For eosinophilic esophagitis, those two stories rarely match. The clinical narrative is a chronic, immune-mediated inflammatory condition of the esophagus, driven largely by food antigens, characterized by eosinophilic infiltration of the esophageal mucosa. The lived narrative is years spent learning how to eat around a body that has turned swallowing into something that must be managed rather than trusted. This program exists because those two narratives need to be brought closer together, and because our team includes people for whom that gap is not theoretical.

## The Odyssey to Diagnosis

For many patients, the path to an EoE diagnosis is long and indirect. Children may present with feeding difficulty, food refusal, or failure to thrive — symptoms that are easy to misattribute to picky eating or reflux. Adolescents and adults more often present with dysphagia and, in a substantial number of cases, an episode of food impaction requiring emergency intervention. Because these symptoms overlap with far more common conditions, and because EoE is confirmed only through esophageal biopsy at endoscopy, diagnosis is frequently delayed by years and often follows multiple procedures — each requiring sedation, each a small ordeal in its own right, each layered onto the anxiety of not knowing what is wrong.

## Living With a Disease That Is Managed, Not Cured

Once diagnosed, patients face a treatment landscape that is genuinely effective for many but fundamentally incomplete. Proton pump inhibitors, swallowed topical corticosteroids, food elimination diets, and biologic therapy such as dupilumab can each reduce eosinophilic inflammation and improve symptoms. But none of these approaches is curative. They require ongoing adherence — daily medication, repeated food reintroduction trials, or continued injections — and inflammation and symptoms typically return when treatment stops. Elimination diets, while drug-free, carry their own burden: they demand vigilance at every meal, complicate social eating, and often require serial endoscopies to test whether a reintroduced food is tolerated. Patients are, in effect, asked to manage this disease indefinitely, with periodic biopsies to confirm that the management is still working.

Left inadequately controlled over time, chronic esophageal inflammation can progress to fibrostenotic disease — strictures and narrowing of the esophagus caused by tissue remodeling that does not reverse with anti-inflammatory treatment alone. This is why patients so often describe not just current symptoms but a quieter, ongoing fear of this disease's future: the possibility of needing esophageal dilation, a mechanical procedure to stretch a narrowed esophagus, sometimes repeatedly, sometimes for the rest of one's life.

## The Burden That Doesn't Show Up in a Biopsy

None of this captures what EoE actually feels like day to day. Patients describe learning to chew every bite an unusual number of times, avoiding foods by texture rather than taste, drinking liquid with every mouthful, and quietly watching how fast others at the table are eating so as not to fall behind or draw attention. Meals — ordinarily a site of connection — can become a site of vigilance. Many patients limit restaurant dining, travel, or social occasions built around food, not because they cannot manage their disease but because managing it in public is exhausting. Anxiety around choking or impaction is common and rational, given how many patients have experienced it. This is a disease that asks for constant, low-grade attention, meal after meal, for life.

## Why an Antigen-Specific Tolerance Approach Matters

Current therapies work by suppressing or blocking the downstream inflammatory response. An antigen-specific tolerance vaccine takes a different aim: retraining the immune system's response to the specific food antigens driving disease, rather than continuously countering the inflammation those antigens provoke. If successful, such an approach could offer something patients consistently say they want most — not just fewer symptoms, but less vigilance. Fewer doses, delivered less frequently than a daily pill or biologic injection, addressing a cause rather than only a consequence, could mean fewer moments of the day organized around managing disease.

That promise is also why patients cannot be a downstream audience for this work. The symptoms worth measuring, the outcomes worth calling success, the burden of a trial's endoscopy schedule, the real-world meaning of "improvement" — these are things patients understand from the inside in ways that no amount of external consultation replaces. Involving patients at every stage of development, from trial design through outcome selection to eventual delivery, is not a gesture. It is how this program stays honest about what it is actually trying to fix.